Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06266416 · ClinicalTrials.gov registry record · NA
IMARA for Black Male Caregivers and Girls Empowerment (IMAGE)
A NA study of HIV Infections and Sexual Behavior, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 612
- Enrollment target
- 1
- Study location
NCT06266416: Recruiting NA study of HIV Infections and Sexual Behavior, sponsored by University of Illinois at Chicago.
NCT06266416 is a NA study of HIV Infections and Sexual Behavior that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 612 participants, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (38% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06266416, a NA study of HIV Infections and Sexual Behavior, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 612 participants
- Enrollment target
- 1
- Study location
Study Summary
The scientific premise of this research is that individual, interpersonal, and structural factors impact Black girls' sexual reproductive health outcomes (sexually transmitted infection (STI) and Human Immunodeficiency Virus (HIV)) and experience of sexual violence. This study expands STI/HIV prevention programs to include Black male caregivers, a potentially valuable yet underutilized resource to protect Black girls and reduce their exposure to STI/HIV and sexual violence.
Primary Outcome
Sexually Transmitted Infection (STI) incidence from the 14-18 year old girls dyad
Conditions Studied
Interventions
- BEHAVIORAL IMARA for Black Male Caregivers and Girls Empowerment
- BEHAVIORAL Time-matched control program
Study Locations (1)
Illinois
- University of Illinois Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 612 participants |
| Start Date | 2024-10-05 |
| Est. Completion | 2028-05-31 |
| Phase | NA |
What NCT06266416 shows while recruiting
NCT06266416 is an interventional study that assigns participants to a tested intervention. The registered 612 participants enrollment target is mid-sized for trials with a published cap, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (38% higher).
The record links to 3 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which IMARA for Black Male Caregivers and Girls Empowerment is the first listed.
NCT06266416 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06266416 about?
NCT06266416 is a clinical study titled "IMARA for Black Male Caregivers and Girls Empowerment (IMAGE)". The scientific premise of this research is that individual, interpersonal, and structural factors impact Black girls' sexual reproductive health outcomes (sexually transmitted infection (STI) and Human Immunodeficiency Virus (HIV)) and experience of sexual violence. This study expands STI/HIV preven...
What is the current status of trial NCT06266416?
This trial is currently recruiting. It is a NA study. The enrollment target is 612 participants. The study started on 2024-10-05. Estimated completion is 2028-05-31.
What conditions does trial NCT06266416 study?
This clinical trial studies the following conditions: HIV Infections, Sexual Behavior, Sexually Transmitted Infections (Not HIV or Hepatitis).
What interventions are being tested in trial NCT06266416?
The interventions under investigation include: IMARA for Black Male Caregivers and Girls Empowerment (BEHAVIORAL), Time-matched control program (BEHAVIORAL).
Who is sponsoring clinical trial NCT06266416?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06266416 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06266416's enrollment target sits among peer trials
612 50th of 542 higher than 493 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04224493 · 612 participants · Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
- NCT04590326 · 612 participants · Phase 1
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab
- NCT01810913 · 613 participants · Phase 2
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
- NCT03821857 · 614 participants · Phase 4
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI